BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33995605)

  • 1. Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation.
    Kuo LT; Lin SJ; Wu VC; Chang JJ; Chu PH; Lin YS
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211011374. PubMed ID: 33995605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
    Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A
    JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Network Meta-Analysis Comparing Osteoporotic Fracture among Different Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation.
    Khanra D; Mukherjee A; Deshpande S; Khan H; Kathuria S; Kella D; Padmanabhan D
    J Bone Metab; 2021 May; 28(2):139-150. PubMed ID: 34130366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Direct Oral Anticoagulants vs. Vitamin K Antagonists With Fractures in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis.
    Wu X; Hu L; Liu J; Gu Q
    Front Cardiovasc Med; 2021; 8():713187. PubMed ID: 34368263
    [No Abstract]   [Full Text] [Related]  

  • 7. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Loh CH
    Eur Heart J; 2020 Mar; 41(10):1100-1108. PubMed ID: 32006423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
    Lorenzoni V; Pirri S; Turchetti G
    Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
    Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
    Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
    Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A
    Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
    Bikdeli B; Zahedi Tajrishi F; Sadeghipour P; Talasaz AH; Fanikos J; Lippi G; Siegal DM; Eikelboom JW; Monreal M; Jimenez D; Connors JM; Ageno W; Barnes GD; Piazza G; Angiolillo DJ; Parikh SA; Kirtane AJ; Lopes RD; Bhatt DL; Weitz JI; Mehran R; Krumholz HM; Goldhaber SZ; Lip GYH
    JAMA Cardiol; 2022 Jul; 7(7):747-759. PubMed ID: 35648414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.
    Binding C; Bjerring Olesen J; Abrahamsen B; Staerk L; Gislason G; Nissen Bonde A
    J Am Coll Cardiol; 2019 Oct; 74(17):2150-2158. PubMed ID: 31648707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.